GENova’s mission is to create a new generation of targeted human therapeutics – safe medicine that works against a variety of cancers and infectious diseases.

• According to the World Health Organisation (2006), cancer accounts for 13 per cent of all deaths worldwide – a devastating disease, characterised by abnormal growth and proliferation of cells which may invade adjacent tissues and spread to other areas of the body.

• Therefore, the market for effective cancer therapeutics is immense, with revenues of US$ 23.6 billion in 2004, projected to rise to US$ 60.6 billion by 2011.

• Even here in the 21st century, cancer treatment regimes are based on highly toxic chemotherapy with significant side-effects. However, new developments are emerging. These are based on targeted therapies directed specifically at the cancer, without harming healthy cells. Analyses predict targeted therapies, such as monoclonal antibodies to drive the total market growth by adding to already developed therapies and attracting and curing new patients.

• Among our proprietary and most promising anti-cancer candidates we include Prostaganin (targeting prostate cancer) and Tetanolic (targeting breast cancer). In preliminary studies they have proven able to target cancer cells without affecting normal tissue – and hence their enormous potential for being developed into blockbuster drugs. In addition, several other oncological candidates are under evaluation.

• Other new technology platforms include an improved method for identification of the cancer stem cells which are the precursors of breast cancer. This interesting and innovative technology will facilitate the identification of unique biomarkers on the precursor cells and thereby lead to their specific destruction.

• One of GENova’s most important emerging indication areas is infectious disease, particularly hospital acquired-infections such as MRSA. In healthcare environments MRSA infections are becoming more prevalent. In 1974, MRSA infections made up two per cent of the total number of infections; in 1995 it was 22 per cent; and in 2004 it was 63 per cent (US Centers for Disease Control, 2007). And the sad news is that the bacteria responsible are getting increasingly resistant to existing antibiotics. That is why one of our promising acquisition candidates will target hospital-acquired infections such as MRSA.

• Our business model relying on worldwide outsourcing, global collaboration, the benefit of advice from leading experts in the field and use of regulatory fast-tracking ensures accelerated drug development – and early exit to larger Biotech or Big Pharma companies with the necessary infrastructure to further develop the products.

• For the benefit of patients and GENova’s partners and investors, revenues gained through licensing activities will be reinvested into research and development of new agents.

back to top